Navigation Links
AtriCure Reports First Quarter 2008 Financial Results
Date:5/6/2008

om domestic open-heart products were $7.0 million, a 6.1% increase over first quarter 2007 revenues of $6.6 million and a $0.3 million sequential decrease. Revenues from domestic minimally invasive products were a record $4.9 million, representing a 65.3% increase over first quarter 2007 revenues of $3.0 million and a sequential increase of $1.0 million, or 26.5%. International revenues were $1.7 million for the first quarter of 2008, a 35.6% increase over first quarter 2007 revenues of $1.2 million and a sequential decrease of $0.3 million.

Gross profit for the first quarter of 2008 was $10.3 million and gross margin was 76.1%, compared to gross profit of $8.5 million and gross margin of 79.4% for the first quarter of 2007. The decrease in gross margin was due primarily to the introduction of new products. Operating expenses were $14.2 million for the first quarter of 2008, a 5.8% increase over first quarter 2007 operating expenses of $13.4 million. The increase in operating expenses as compared with the first quarter of 2007 was primarily driven by an increase in selling expenses.

The net loss for the first quarter of 2008 was $3.6 million as compared to a $4.3 million net loss for the first quarter of 2007, an improvement of 16.2%. Net loss per share was $0.25, an improvement of 28.6%, or $0.10 per share, as compared to the first quarter 2007 net loss per share of $0.35. The improvement in the net loss per share for the first quarter of 2008 as compared with the first quarter of 2007 was primarily due to increased net income and an increase in shares outstanding, due primarily to the issuance of 1.8 million shares of our common stock in a May 2007 private placement transaction.

Cash, cash equivalents and investments at March 31, 2008 were $14.9 million.

Financial Guidance

The Company is confirming its full year 2008 guidance of $58 to $60 million for revenues and an expected net loss per share between $0.55 and $0.70.

Con
'/>"/>

SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
3. Vion Reports 2008 First Quarter Results
4. eResearchTechnology Reports First Quarter 2008 Results
5. MannKind Corporation Reports First Quarter Financial Results
6. Verenium Reports Financial Results for the First Quarter 2008
7. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
8. United Therapeutics Reports First Quarter 2008 Financial Results
9. Endocare Reports 2008 First Quarter Financial Results
10. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
11. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Boston, MA (PRWEB) August 29, 2014 Due ... (FRC) last week, the Adult Stem Cell Technology Center, ... donations to support stem cell therapy research that might benefit ... adult stem cells for new stem cell technologies and therapeutic ... ALS Ice Bucket Challenge donors who wish not ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 Best ... products for the food processing industry, is asking industry ... side-by side comparison of the E2 soap they’re currently ... Sanitizing Foam Soap . Hand hygiene is critical ... the food processing environment. Six key criteria are identified ...
(Date:8/28/2014)... MA (PRWEB) August 28, 2014 “This kit ... test to screen from 0 to 150 ppb,” said Mark ... is a significant benefit to plant owners and USDA-GIPSA inspection ... and other commodities. Testing can take place in a matter ... only can the plant test the feed and grain before ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... Calif., Dec. 12 Codexis, Inc., a leading,developer ... directors have been named to the company,s Board ... Vice President of Innovation and,Chemicals Technology, Shell Global ... Dennis Wolf, Executive Vice President and CFO, MySQL, ...
... PLYMOUTH MEETING, Pa., Dec. 12 Genaera,Corporation (Nasdaq: ... Executive Officer of Genaera, is scheduled to present at ... part of an,RBC Capital Markets, panel discussion of diabetes ... and will take place in,New York on Thursday, December ...
... First Time on 50 mg/Day Dose for PRISTIQ for the ... Treatment of Major Depressive ... of Wyeth (NYSE: WYE ), announces that data from,two ... inhibitor (SNRI), showed,that adult patients who received a 50 mg/day ...
Cached Biology Technology:Rothwell, Wolf Elected to Codexis Board 2Rothwell, Wolf Elected to Codexis Board 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:9/1/2014)... animals, bats are perfectly adapted to a life without light. ... reflected echoes to measure distance to obstacles or prey. In ... delays. A study carried out by researchers at Technische Universitt ... map dynamically adapts to external factors. , Closer ... in too close to an object, the number of activated ...
(Date:8/31/2014)... sniffing the highly infectious bacteria C. diff , ... developed by a team at the University of Leicester. ... demonstrated that it is possible to identify the unique ... to rapid diagnosis of the condition., What is more, ... identify different strains of the disease simply from their ...
(Date:8/31/2014)... Change , suggests that if current trends continue ... targets for total greenhouse gas (GHG) emissions in 2050. ... about the food we choose and its environmental impact. A ... of a number of actions that need to be taken ... food for all. , As populations rise and global ...
Breaking Biology News(10 mins):Zooming in for a safe flight 2Scientists develop 'electronic nose' for rapid detection of C. diff infection 2Changing global diets is vital to reducing climate change 2Changing global diets is vital to reducing climate change 3Changing global diets is vital to reducing climate change 4
... into a calcium-sensing enzyme already known to play a ... researchers showed that the enzyme, calmodulin kinase II (CaM ... disease called Timothy syndrome and that inhibiting the enzyme ... a new cellular model, could help with developing treatments ...
... Climate change can have significant impacts on high-elevation lakes ... them, according to U.S. Forest Service and University of ... issue of the journal " Herpetological Conservation and Biology ... shallow lakes drying up in summer and predation by ...
... at The University of Queensland could contribute to the ... virus and Dengue fever. Led by Associate ... School of Molecular and Microbial Sciences identified a novel ... belong. The team found all flaviviruses produced ...
Cached Biology News:Rare disease provides clues about enzyme role in arrhythmias 2Rare disease provides clues about enzyme role in arrhythmias 3Climate change effects on imperiled Sierra frog examined 2UQ research targets West Nile virus and dengue fever 2
NORMAL DONOR DONKEY SERUM...
... EPS 301 Power Supply, 1. ... maximum.Constant voltage or constant current modes.Single-unit ... precision and reproducibility.Suitable for submarine, mini ... as well as semidry and mini ...
B3-1...
Human CCL26/Eotaxin-3 MAb (Clone 115002)...
Biology Products: